Jan
2016
Projects : International studies
Submission of a phase II in EU   -  first line for patient unresponding to TMZ.
Submission of a phase I in Australia -  first line  combined with RT.
 
Jan
2015
« Seal of excellence » in project development from European Commission. 
Jan
2014
ERC own GMP facilities (the Netherlands) and tissue bank.
Acquisition of the patent:   PCT/US11/57654
Vaccine, Therapeutic Composition and Methods for Treating or Inhibiting Glioblastoma 
Jan
2013
Phase II FDA Approval in recurrent patients - recruiting.
Orphan Drug Status granted by EMA.                               
Nov
2012
Submission of application for EMA orphan drug designation.
Compassionate use in Canada considered by approval authorities. (Health Canada)
Confirmation for NID protocol meeting (FDA) schedule on January 9th, 2013.
Sep
2012
First patient reaching total remission.
May
2012
Single patient INDs 15022 and 15087 granted by US FDA.
Mar
2012
Second patient vaccinated in Belgium also for compassionate use.
Jan
2012
The company has designed and initiated a 15 month pre-clinical development plan which will allow it to apply for a Phase I/II clinical trial in glioblastoma patients.
First vaccination of patients under compassionate use.
Jan
2011
The company obtained Orphan Drug status for Gliovac/ERC1671 from the US FDA.
The company obtained the status SME from the EMA which offers significant advantages in terms of fee waivers for EMA guidance and assessments of marketing authorization applications.
The company has put into place a scientific team with experience in cell culture and set up two scientific advisory boards, one in Europe and one in the United States.
Oct
2010
Published article on the successful and statistically significant preclinical animal tests (conducted in rats having two strains of malignant gliomas); e.g. Anit-cancer Agents in Medicinal Chemistry, 2010, Vol. 10, No. 6; Hofman et al.
Oct
2009
The company obtained Advanced Medical Therapy Product status for Gliovac/ERC1671 from the EMA. (classification: somatic cell therapy)
Jul
2009
Erc settled in its main office in Isnes. (Belgium)
Implementation of a "cleanroom" at the Hospital of South of Luxembourg in Arlon (Belgium) with the set-up of tissue bank, whereby the clinical trials of the company can be compliant with EU standards.
Feb
2008
Creation of ERC.
Jan
2007
Patent.  PCT/EP2007/050807 (WO/2007/085648)
Tumor Vaccine Comprising Allogeneic or Xenogeneic tumor cells.
Jan
2006
Proof-of-Concept
Stathopoulos, A., C et al. (2008) Therapeutic vaccination against malignant gliomas based on allorecognition and syngeneic tumor antigens proof of principle in two strains of rat.